Gene expression changes in multiple sclerosis relapse suggest activation of T and non-T cells

Molecular Medicine

Volumn 17, Issue 1-2, 2011, Pages 95-102

  Lindsey, J William ^a   Agarwal, Sandeep K ^b   Tan, Filemon K ^b  

^a Department of Neurology ^*  (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GLATIRAMER; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; MESSENGER RNA;

ARTICLE; BLOOD CLOTTING; CLINICAL ARTICLE; COMPLEMENT SYSTEM; CONTROLLED STUDY; FEMALE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; MALE; MICROARRAY ANALYSIS; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REGULATORY MECHANISM; RELAPSE; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION;

GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; MOLECULAR SEQUENCE DATA; MULTIPLE SCLEROSIS; RECURRENCE; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 78651496815     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/molmed.2010.00071     Document Type: Article

References (31)

1. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. (2000) Multiple sclerosis. N. Engl. J. Med. 343:938-952.
2. Sibley WA, Bamford CR, Clark K. (1985) Clinical viral infections and multiple sclerosis. Lancet. 1:1313-1315.
3. Buljevac D, et al. (2002) Prospective study on the relationship between infections and multiple sclerosis exacerbations. Brain. 125:952-960.
4. Polman CH, et al. (2006) A randomized, placebocontrolled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 354:899-910.
5. Achiron A, Gurevich M, Friedman N, Kaminski N, Mandel M. (2004) Blood transcriptional signatures of multiple sclerosis: unique gene expression of disease activity. Ann. Neurol. 55:410-7.
6. Arthur AT, et al. (2008) Genes implicated in multiple sclerosis pathogenesis from consilience of genotyping and expression profiles in relapse and remission. BMC Med. Genet. 9:17.
7. Malmestrom C, et al. (2008) Relapses in multiple sclerosis are associated with increased CD8(+) T-cell mediated cytotoxicity in CSF. J. Neuroimmunol. 196:159-165.
8. Satoh J, Misawa T, Tabunoki H, Yamamura T. (2008) Molecular network analysis of T-cell transcriptome suggests aberrant regulation of gene expression by NF-kappaB as a biomarker for relapse of multiple sclerosis. Dis. Markers. 25:27-35.
9. Wright GW, Simon RM. (2003) A random variance model for detection of differential gene expression in small microarray experiments. Bioinformatics. 19:2448-2455.
10. Dillon SP, D'Souza A, Kurien BT, Scofield RH. (2009) Systemic lupus erythematosus and C1q: A quantitative ELISA for determining C1q levels in serum. Biotechnol. J. 4:1210-1214.
11. Lu JH, et al. (2008) The classical and regulatory functions of C1q in immunity and autoimmunity. Cell. Mol. Immunol. 5:9-21.
12. Christophi GP, et al. (2009) Macrophages of multiple sclerosis patients display deficient SHP-1 expression and enhanced inflammatory phenotype. Lab. Invest. 89:742-759.
13. Achiron A, Feldman A, Mandel M, Gurevich M. (2007) Impaired expression of peripheral blood apoptotic-related gene transcripts in acute multiple sclerosis relapse. Ann. N. Y. Acad. Sci. 1107:155-167.
14. Gurevich M, Tuller T, Rubinstein U, Or-Bach R, Achiron A. (2009) Prediction of acute multiple sclerosis relapses by transcription levels of peripheral blood cells. BMC Med. Genomics. 2:46.
15. Brynedal B, et al. (2009) Gene expression profiling in multiple sclerosis: A disease of the central nervous system, but with relapses triggered in the periphery? Neurobiol. Dis. 37:613-621.
16. Ramanathan M, et al. (2001) In vivo gene expression revealed by cDNA arrays: the pattern in relapsing- remitting multiple sclerosis patients compared with normal subjects. J. Neuroimmunol. 116:213-219.
17. Corvol JC, et al. (2008) Abrogation of T cell quiescence characterizes patients at high risk for multiple sclerosis after the initial neurological event. Proc. Natl. Acad. Sci. U. S. A. 105:11839-11844.
18. Bomprezzi R, et al. (2003) Gene expression profile in multiple sclerosis patients and healthy controls: identifying pathways relevant to disease. Hum. Mol. Genet. 12:2191-2199.
19. Iglesias AH, et al. (2004) Microarray detection of E2F pathway activation and other targets in multiple sclerosis peripheral blood mononuclear cells. J. Neuroimmunol. 150:163-177.
20. De Jager PL, et al. (2009) Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nat. Genet. 41:776-782.
21. (2009) Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20. Nat. Genet. 41:824-828.
22. Cojocaru M, Serbanescu A, Cojocaru IM. (1993) Changes of serum complement and of circulating immune complexes in patients with multiple sclerosis. Rom. J. Intern. Med. 31:131-137.
23. Glass WG, Sarisky RT, Vecchio AM. (2006) Not-sosweet sixteen: the role of IL-16 in infectious andimmune-mediated inflammatory diseases. J. Interferon Cytokine Res. 26:511-520.
24. Skundric DS, Cai J, Cruikshank WW, Gveric D. (2006) Production of IL-16 correlates with CD4+ Th1 inflammation and phosphorylation of axonal cytoskeleton in multiple sclerosis lesions. J. Neuroinflammation. 3:13.
25. Skundric DS, Zhou W, Cruikshank WW, Dai R. (2005) Increased levels of bioactive IL-16 correlate with disease activity during relapsing experimental autoimmune encephalomyelitis (EAE). J. Autoimmun. 25:206-214.
26. Annibali V, et al. (2007) Gene expression profiles reveal homeostatic dynamics during interferonbeta therapy in multiple sclerosis. Autoimmunity. 40:16-22.
27. Feakes R, et al. (2000) Interleukin 1 receptor antagonist (IL-1ra) in multiple sclerosis. J. Neuroimmunol. 105:96-101.
28. Comabella M, et al. (2008) Induction of serum soluble tumor necrosis factor receptor II (sTNFRII) and interleukin-1 receptor antagonist (IL- 1ra) by interferon beta-1b in patients with progressive multiple sclerosis. J. Neurol. 255:1136-1141.
29. Burger D, et al. (2009) Glatiramer acetate increases IL-1 receptor antagonist but decreases T cellinduced IL-1beta in human monocytes and multiple sclerosis. Proc. Natl. Acad. Sci. U. S. A. 106:4355-4359.
30. Nicoletti F, et al. (1996) Circulating serum levels of IL-1ra in patients with relapsing remitting multiple sclerosis are normal during remission phases but significantly increased either during exacerbations or in response to IFN-beta treatment. Cytokine. 8:395-400.
31. Dettke M, Scheidt P, Prange H, Kirchner H. (1997) Correlation between interferon production and clinical disease activity in patients with multiple sclerosis. J. Clin. Immunol. 17:293-300.